Skip to main content

Why COVID-19 pneumonia is worse than typical pneumonia

 

Why COVID-19 pneumonia is worse than typical pneumonia

COVID-19 pneumonia spreads like multiple wildfires, leaving destroyed lung tissue in its wake







Bacteria or viruses like influenza that cause pneumonia can spread across large regions of the lung over the course of hours. In the modern intensive care unit, these bacteria or viruses are usually controlled either by antibiotics or by the body's immune system within the first few days of the illness.

But in a study published in Nature on January 11, investigators at Northwestern Medicine show COVID-19 pneumonia is different.

Instead of rapidly infecting large lung regions, the virus causing COVID-19 sets up shop in multiple small areas of the lung. It then hijacks the lungs' own immune cells and uses them to spread across the lung over a period of many days or even weeks, like multiple wildfires spreading across a forest. As the infection slowly moves across the lung, it leaves damage in its wake and continuously fuels the fever, low blood pressure, and damage to the kidneys, brain, heart, and other organs in patients with COVID-19.

The severe complications of COVID-19 compared with other pneumonia might be related to the disease's long course rather than a more severe disease, the study authors said.

This is the first study in which scientists analyzed immune cells from the lungs of COVID-19 pneumonia patients systematically and compared them to cells from patients with pneumonia from other viruses or bacteria.

Drug trial to treat newly discovered targets in COVID-19 pneumonia

As a result of the detailed analysis, researchers identified critical targets to treat severe SARS-CoV-2 pneumonia and lessen its damage. The targets are the immune cells: macrophages and T cells. The study suggests macrophages -- cells typically charged with protecting the lung -- can be infected by SARS-CoV-2 and contribute to spreading the infection through the lung.

Northwestern Medicine will test an experimental drug to treat these targets in COVID-19 pneumonia patients in a clinical trial early in 2021. The drug to be tested quiets these immune cells' inflammatory response, thus enabling the repair process in the injured lung.

Aim to make COVID-19 like a bad cold

"Our goal is to make COVID-19 mild instead of severe, making it comparable to a bad cold," said study co-senior author Dr. Scott Budinger, chief of pulmonary and critical care medicine at Northwestern University Feinberg School of Medicine and Northwestern Medicine.

"This effort truly represents a 'moonshot' in COVID-19 research," said study co-senior author Dr. Richard Wunderink, professor of pulmonary and critical care medicine at Feinberg and medical director of Northwestern Medicine's ICU.

COVID-19 unlikely to completely disappear

COVID-19, like influenza, is unlikely to ever go away, even if much of the population is vaccinated, said senior co-author Dr. Ben Singer, assistant professor of pulmonary and critical care medicine at Feinberg and a Northwestern Medicine physician.

"Already, researchers at Northwestern and elsewhere are anticipating mechanisms by which this RNA virus, which mutates quickly, will evade current vaccines," Singer said. "This study will help us develop treatments to reduce the severity of COVID-19 in those who develop it."

Mortality in COVID-19 patients on ventilators lower than regular pneumonia patients

The study also revealed why patients' mortality on a ventilator for COVID-19 was lower than patients on a ventilator due to regular pneumonia, the study reports. An intense conflagration in the lungs (regular pneumonia) has a higher risk of death. Those with COVID-19 pneumonia are sick for a long time, but their lungs' inflammation is not as severe as regular pneumonia.

"If patients with COVID-19 are carefully managed, and the health care system isn't overwhelmed, you can get them through it," Budinger said. "These patients are very sick. It takes a really long time for them to get better. But If you have enough beds and health care providers, you can keep the mortality to 20%. When health systems are overwhelmed, mortality rates double up to 40%."

For the study, scientists performed a high-resolution analysis of the lung fluid of 86 COVID-19 patients on a ventilator and compared it with lung fluid from 256 patients on a ventilator who had other types of pneumonia. Because of the safety concerns, only a handful of groups worldwide performed an analysis of the immune response in patients' lungs with COVID-19. As a result, important information about what was killing patients with severe COVID-19 was missing.

Northwestern scientists, studying pneumonia for years, poised for COVID lung research

The study performed at Northwestern Medicine is unique because Wunderink and colleagues studied pneumonia for years before the pandemic. As a result, when the COVID-19 pandemic hit, they were prepared to safely and systematically collect fluid from these patients' lungs and compare it with fluid collected from other ICU patients with pneumonia collected before the pandemic. This research infrastructure allowed them to show that pneumonia in patients with COVID-19 is different from other pneumonia, and more importantly, how it is different.

Scientists took cells from patients' lung fluid and looked at the RNA and the proteins those cells express, enabling them to identify how these immune cells drive inflammation.

"This level of resolution could never be achieved without directly sampling lung fluid," said study co-senior author Dr. Alexander Misharin, an assistant professor of pulmonary and critical care medicine at Feinberg and a Northwestern Medicine physician.

The study's complex nature, in which samples from patients were analyzed with the most sophisticated technologies available in Northwestern's state-of-the-art research labs, required the concerted effort of more than 100 researchers.

The first authors are Rogan Grant, Luisa Morales-Nebreda, and Nikolay Markov. Grant is a graduate student in the Northwestern University Interdepartmental Neuroscience program; Dr. Luisa Morales-Nebreda is a pulmonary and critical care fellow in the Physician Scientist Training Program at Northwestern; Nikolay Markovis is a computational postdoctoral fellow in the division of pulmonary and critical care medicine.

The work was done as part of a consortium of investigators participating in the Successful Clinical Response in Pneumonia Therapy Systems Biology Center funded by the National Institute of Allergy and Infectious Diseases led by Wunderink.

The research was supported by a NUCATS COVID-19 Rapid Response Grant and grants T32AG020506-18, by T32HL076139 and F32HL151127, HL145478, HL147290, HL147575, GM129312, HL134800, U19AI135964, P01AG049665, P01AG04966506S1, R01HL147575, I01CX001777, U19AI135964, P01AG049665, R56HL135124, R01HL153312, K08HL128867, U19AI135964, R01HL149883, and P01AG049665 from the National Institutes of Health. It also was funded by a GlaxoSmithKline Distinguished Scholar in Respiratory Health grant from the CHEST Foundation.


Comments

Popular posts from this blog

CRACKING COCONUT OIL'S " HEALTH HALO"

Cracking coconut oil’s "health halo" Thanks to marketing strategies that tout coconut oil as healthy, many people consider this solid, white fat a portion of healthy food. But a new analysis confirms what nutrition experts have said for years: Coconut oil raises harmful LDL cholesterol (a well-known contributor to heart disease) much more than other vegetable oils. The study, published online March 10, 2020, by the journal  Circulation , pooled findings from 16 trials involving a total of 730 people. Most of the trials lasted one to two months and compared coconut oil consumption with that of other fats, including other vegetable oils such as soybean, safflower, canola, and olive oils. Compared with these vegetable oils, coconut oil raised LDL cholesterol by 10 points, on average. An editorial accompanying the study states "In culinary practice, coconut oil should not be used as regular cooking oil, although it can be used sparingly for flavor or texture.

Autophagy:The Body's Anti-aging process

Autophagy: The body's Anti-aging process Autophagy is how the body removes and recycles dangerous, and damaged organelles and particles, as well as pathogens, from inside cells, thus aiding your immune system and greatly reducing your risk of developing cancer, heart disease, chronic inflammation, osteoarthritis, and neurological disorders such as depression and dementia. Autophagy makes us physiologically more efficient by getting rid of defective parts, promoting healthy metabolism, stopping cancerous growths, and preventing metabolic disorders such as diabetes and obesity --- which means that by boosting your body's autophagy, you dampen inflammation, slow down the aging process, reduce your risk of developing certain diseases, and optimize your biological function. The autophagy process is activated by intermittent fasting and calorie restriction. Intermittent fasting and calorie restriction turn up the autophagy dial, increasing protein turnover and cellular repai

HOW TO LOWER YOUR CHOLESTEROL WITHOUT DRUGS

How to lower your cholesterol without drugs You can begin to reduce your “bad” LDL cholesterol by making a few simple changes in your diet. If your cholesterol is creeping upward, your doctor has probably told you that diet and exercise — the traditional cornerstones of heart health — could help to bring it down. And if you’d prefer to make just one change at a time, you might want to begin with your diet. A major 2012 analysis of several controlled trials involving hundreds of men and women found that dietary changes reduced LDL and total cholesterol while exercise alone had no effect on either. (However, adding aerobic exercise did enhance the lipid-lowering effects of a heart-healthy diet.) The people in the studies followed a variety of diets, from the Mediterranean to low-fat to low-calorie. However, the most effective diets substituted foods with cholesterol-lowering power for those that boost cholesterol. According to Kathy McManus, director of the Department of Nutrition at Bri